If you have been reading about GIP receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-09. Numbers and descriptions here follow the published literature rather than marketing material.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Approximate composition of the free peptide |
| Molecular weight | Approximately 4813 Da | Calculated for the free base |
| Structural class | Synthetic linear peptide | 39 residues with modified backbone |
| Solubility | Soluble in water and polar solvents | Behavior of the lyophilized solid |
| Typical storage temperature | -20 degrees Celsius or below | Solid form, protected from light |
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
=== Digestive health === Peppermint can be used to relieve symptoms of irritable bowel syndrome (IBS). Peppermint oil reduces muscle contraction in the gastrointestinal tract by inhibiting calcium inflow. It may also reduce inflammation, nausea, and discomfort by influencing serotonin and cholinergic receptors.
Linus Carl Pauling was born on February 28, 1901, in Portland, Oregon, the firstborn child of Herman Henry William Pauling (1876–1910) and Lucy Isabelle "Belle" Darling (1881–1926). He was named "Linus Carl", in honor of Lucy's father, Linus, and Herman's father, Carl. His ancestry included German and English-Scottish. In 1902, after his sister Pauline was born, Pauling's parents decided to move out of Portland to find more affordable and spacious living quarters than their one-room apartment. Lucy stayed with her husband's parents in Lake Oswego until Herman brought the family to Salem, where he worked briefly as a traveling salesman for the Skidmore Drug Company. Within a year of Lucile's birth in 1904, Herman Pauling moved his family to Lake Oswego, Oregon where he opened his own drugstore. He moved his family to Condon, Oregon, in 1905. By 1906, Herman Pauling was suffering from recurrent abdominal pain. He died of a perforated ulcer on June 11, 1910, leaving Lucy to care for Linus, Lucile and Pauline. Pauling attributes his interest in becoming a chemist to being amazed by experiments conducted by a friend, Lloyd A. Jeffress, who had a small chemistry lab kit. He later wrote: "I was simply entranced by chemical phenomena, by the reactions in which substances, often with strikingly different properties, appear; and I hoped to learn more and more about this aspect of the world." In high school, Pauling conducted chemistry experiments by scavenging equipment and material from an abandoned steel plant.
== Expansion == Between 1993 and 1995 five new establishments were opened, and today it has a total of 72 restaurants; 63 in Madrid, 5 in Valencia, 2 in Barcelona, 2 in Sevilla, 1 in Toledo and 1 in Segovia. There is also at least one location in Malaga. In 1995, the company sold approximately 1.5 million sandwiches per month. Already controlled by the brewery Damm since 2012, the Grupo Rodilla was fully bought by Damm in 2015.
It was instrumental in the Red Terror and Great Purge, but was brought under strict party control after Stalin's death. Under Yuri Andropov, the KGB engaged in the suppression of political dissent and maintained an extensive network of informers, reasserting itself as a political actor to some extent independent of the party-state structure, culminating in the anti-corruption campaign targeting high-ranking party officials in the late 1970s and early 1980s.
==== Finland ==== In Finland the qualification of medical physicist is comparable to specialisation of physicians. In contrast to many other countries, qualified medical physicist is considered as a post-graduate university education requiring a licentiate's degree or a PhD and a 5-year training residency.
Sources: en.wikipedia.org
== Technology and product offerings == Seer's proteomics platform integrates engineered nanoparticles, automated sample preparation, and mass spectrometry. It utilizes nanoparticles with different physicochemical properties, including size, charge, and hydrophobicity, to separate and enrich proteins from biological samples, thereby addressing common issues related to dynamic range and sample complexity in proteomics. Seer's platform enables deep, unbiased proteomic analysis, allowing researchers to identify proteins associated with disease or therapeutic response without relying on prior assumptions. A 2020 study published in Nature Communications demonstrated that these nanoparticles form distinct protein coronas, enabling high-depth, parallel profiling of the plasma proteome. Independent benchmark studies indicate that nanoparticle-based plasma proteomics workflows significantly enhance proteome depth and improve quantitative precision when compared to traditional neat-plasma methods. These studies report approximately 3 to 6 times more protein identifications and about twice the reproducibility in independent side-by-side experiments. As of 2025, 58 papers have been published related to the Proteograph, including in journals such as Nature, Nature Communications, Nature Aging, and Cell Metabolism. Among these, a 2025 Nature Aging study reported the identification of more than 10,000 proteins, underscoring the Proteograph platform’s depth in studies at scale.
=== Derivatives === Identified uses for DMPEA includes the following list of agents: 1. Bevantolol. 2. Bisobrin 3. Bometolol 4. Buquiterine 5. Denopamine 6. Dobutamine 7. Dopamine 8. Dopexamine 9. Dramedilol 10. Drotaverine 11. Ecastolol 12. Falipamil 13. Gallopamil 14. Methopholine 15. Mixidine 16. Mefeclorazine 17. Nigellimine [4594-02-9] 18. Nuciferine 19. Papaverine 20. Tetrabenazine 21. Tiapamil 22. Trimethoquinol 23. Veradoline 24. Verapamil.
{\displaystyle Q=\left[m_{\text{N}}\left({\ce {^{\mathit {A}}_{\mathit {Z}}X}}\right)-m_{\text{N}}\left({\ce {^{\mathit {A}}_{{\mathit {Z}}+1}X'}}\right)-m_{\text{e}}-m_{{\overline {\nu }}_{\text{e}}}\right]c^{2}}
Shakey's Pizza was founded in Sacramento, California, on April 30, 1954, by Sherwood "Shakey" Johnson and Ed Plummer. Johnson's nickname resulted from nerve damage following a bout of malaria suffered during World War II. The parlor opened on a weekend, but since the pizza ovens were not yet completed, only beer was served. Shakey took the profits from beer sales and bought ingredients for pizza the following Monday. Shakey personally played Dixieland jazz piano to entertain patrons. He also hired the original members of the Silver Dollar Jazz Band, paying the musicians $10 each plus all the beer and pizza they wanted (Shakey soon realized it was cheaper to pay the musicians scale). This brought the music of Lu Watters to the Sacramento area, causing a local sensation. Jazz historian K.O. Eckland has given the band the credit for the jazz revival in Sacramento that extended to the formation of the Sacramento Traditional Jazz Society. Shakey's also became known outside Sacramento, not for its pizza, but for the jazz program it sponsored on a regional radio network. Shakey Johnson is honored in the American Banjo Museum in Oklahoma City, Oklahoma, for his longtime use of banjo music at his pizza parlors. Other live music, including piano, was also a staple in the old Shakey's parlors. Up until the early 1970s, printed menus included lyrics to classic barbershop songs so that the customers could sing along with the band while their meals were being prepared.
The surface of the rough endoplasmic reticulum (often abbreviated RER or rough ER; also called granular endoplasmic reticulum) is studded with protein-manufacturing ribosomes giving it a "rough" appearance (hence its name). The binding site of the ribosome on the rough endoplasmic reticulum is the translocon. However, the ribosomes are not a stable part of this organelle's structure as they are constantly being bound and released from the membrane. A ribosome only binds to the RER once a specific protein-nucleic acid complex forms in the cytosol. This special complex forms when a free ribosome begins translating the mRNA of a protein destined for the secretory pathway. The first 5–30 amino acids polymerized encode a signal peptide, a molecular message that is recognized and bound by a signal recognition particle (SRP). Translation pauses and the ribosome complex binds to the RER translocon where translation continues with the nascent (new) protein forming into the RER lumen and/or membrane. The protein is processed in the ER lumen by an enzyme (a signal peptidase), which removes the signal peptide. Ribosomes at this point may be released back into the cytosol; however, non-translating ribosomes are also known to stay associated with translocons. The membrane of the rough endoplasmic reticulum is in the form of large double-membrane sheets that are located near, and continuous with, the outer layer of the nuclear envelope.
Sources: en.wikipedia.org
That [RnO3F]− did not form in other experiments may have been due to the high concentration of fluoride used. Electromigration studies also suggest the presence of cationic [HRnO3]+ and anionic [HRnO4]− forms of radon in weakly acidic aqueous solution (pH > 5), the procedure having previously been validated by examination of the homologous xenon trioxide. The decay technique has also been used. Avrorin et al. reported in 1982 that 212Fr compounds cocrystallised with their caesium analogues appeared to retain chemically bound radon after electron capture; analogies with xenon suggested the formation of RnO3, but this could not be confirmed. It is likely that the difficulty in identifying higher fluorides of radon stems from radon being kinetically hindered from being oxidised beyond the divalent state because of the strong ionicity of radon difluoride (RnF2) and the high positive charge on radon in RnF+; spatial separation of RnF2 molecules may be necessary to clearly identify higher fluorides of radon, of which RnF4 is expected to be more stable than RnF6 due to spin–orbit splitting of the 6p shell of radon (RnIV would have a closed-shell 6s26p21/2 configuration). Therefore, while RnF4 should have a similar stability to xenon tetrafluoride (XeF4), RnF6 would likely be much less stable than xenon hexafluoride (XeF6): radon hexafluoride would also probably be a regular octahedral molecule, unlike the distorted octahedral structure of XeF6, because of the inert pair effect.
Proprotein convertases (PPCs) are a family of proteins that activate other proteins. Many proteins are inactive when they are first synthesized, because they contain chains of amino acids that block their activity. Proprotein convertases remove those chains and activate the protein. The prototypical proprotein convertase is furin. Proprotein convertases have medical significance, because they are involved in many important biological processes, such as cholesterol synthesis. Compounds called proprotein convertase inhibitors can block their action, and block the target proteins from becoming active. Many proprotein convertases, especially furin and PACE4, are involved in pathological processes such as viral infection, inflammation, hypercholesterolemia, and cancer, and have been postulated as therapeutic targets for some of these diseases.
Other traditional triglyceride lipases (EC 3.1.1.3) include Lipase member N, DDHD2, PNLIPRP3, PNPLA4, and PNPLA5. In addition, there are various other non-traditional lipases including Monoacylglycerol lipases (eg: MGLL, ABHD2, and ABHD6), and Diacylglycerol lipases (eg: DAGLA, DAGLB, and ABHD11). Not all lipase-family proteins function as lipases in humans. Some like Lipase member H and Lipase member I function as phospholipases, while others like pancreatic lipase related protein 1 (PNLIPRP1), LIPJ, LIPK, and LIPM do not (yet) have a well established function as an enzyme.
=== Age-related macular degeneration === A Cochrane review concluded that there were no changes seen for risk of developing age-related macular degeneration (AMD) from long-term vitamin E supplementation and that supplementation may slightly increase the chances of developing late AMD.
=== Patient information === Blood Transfusion Leaflets (NHS Blood and Transplant) Blood Transfusion Leaflets (Welsh Blood Service) Blood Transfusion Information (Scotland) Blood Transfusion Information (Australia) Blood Transfusion Information (American Cancer Society)
Sources: en.wikipedia.org
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.
Single-receptor agents act predominantly at GLP-1R. Tirzepatide retains activity at GIPR, which is expressed in pancreatic islets, adipose tissue, and the central nervous system. The contribution of each receptor to the overall response is still an area of active study, and the relative weight of GIPR signaling in humans is not fully settled.
The fatty diacid moiety binds serum albumin, which reduces renal filtration of the active peptide. Additional resistance to enzymatic breakdown comes from non-natural residues in the backbone. Together these features produce an apparent half-life of about five days and permit weekly dosing intervals.
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.